About OUR ORGANIZATION

We're a non-profit that grows and connects the longevity industry.

The Longevity Biotech Fellowship is a non-profit community for people to come together to build, join, or invest in revolutionary longevity biotechnology projects.

We operate as an IRS-approved 501(c)3 non-profit --  registered under LessDeath Inc -- based in Santa Clara, California.

Read more about LessDeath's structure and charitable status, here.

Our core Values

The DNA of our Organization.

Postive-sum

We celebrate the wins of all people working to expand the boundless frontier of healthy human lifespan.

Mission-driven

We believe that longevity is the ultimate purpose of technology and the highest leverage fulcrum to reduce suffering.

Called to serve

It is our duty and joy to serve the longevity community in order to accelerate growth and speed up development of aging interventions.

Leadership Team

Meet the team behind the Longevity Biotech Fellowship

Contact us
Mark Hamalainen
Co-Executive Director

Mark’s career has progressed from manual bench work in academia, to lab automation at Synthego, to longevity movement building - always seeking better methods and higher leverage ways to accelerate progress.

Nathan Cheng
Co-Executive Director

Nathan is a physics PhD dropout who made the jump to longevity, first by  writing the most read longevity  investing newsletter, then founding the ODLB community and Healthspan Capital - he wants to inspire others to make the similar leaps.

Jun Axup
Director

Experienced as a scientist, entrepreneur and VC Partner at IndieBio. Jun enjoys applying her multifaceted perspective to advising and inspiring people on how to achieve their goals and build a better future.

Matthew O'Connor
Director

Dr. O’Connor has Ph.D. in Biochemistry from Baylor College of Medicine. His postdoctoral research included work at UC Berkeley on muscle stem cells and aging. He is the former VP of Research at SENS Research Foundation and is currently the CEO of Cyclarity Therapeutics.

Roland Graser
Europe Regional Director

Roland is building the European LBF community with his insights from ontology and the shamanic world. He is early in his career and transitioned from tech startups to clinical research. 

Cat Thu Nguyen Huu
Longevity Course Lead

Cat has a background in software engineering and venture capital. She is a core member at VitaDAO and ran the Longevity Zero to One course at Zuzalu. Now, she's working to build the LBF Longevity Course.

Sean Shelley-Tremblay
Operations Lead

Sean is a communication generalist with experience in biology and policy. He’s been hardwiring his life for ending aging since age 17. He most recently worked at the Alliance for Longevity Initiatives to establish the Longevity Science Caucus in Congress.

Michael Florea
Bottlenecks Proj. Lead

Dr. Florea completed his PhD at Harvard Medical School in 2023 with a focus on gene delivery technology. He is the CEO and co-founder of a stealth longevity techbio co. Amongst many other side projects, he is the team lead for the LBF Bottlenecks to Progress community project.

Our journey

Started from the bottom, now we're here.

We started
Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative
Learn More
5 years later, we're proud of our journey
Co-founders Allie McKenna and Jack had their fingers crossed as Unicorns went into beta exist to help haveing testing.
Learn More
5 years later, we're proud of our journey
Co-founders Allie McKenna and Jack had their fingers crossed as Unicorns went into beta exist to help haveing testing.
Learn More
5 years later, we're proud of our journey
Co-founders Allie McKenna and Jack had their fingers crossed as Unicorns went into beta exist to help haveing testing.
Learn More
Join our team

Put an impact on the world, Joining space.

No items found.
Get INVOLVED IN LONGEVITY.

Join the #1 community for longevity biotech.

Join waitlist

Apply now for the next onboarding retreat on January 18-21!
Application deadline December 31st.